Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

Stock Research Monitor: ARNA, ARWR, and ATRA

ARQL : 5.38 (+3.26%)
ARNA : 43.82 (-1.55%)
Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran...

ARNA : 43.82 (-1.55%)
Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors

SAN DIEGO , July 10, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic...

ARNA : 43.82 (-1.55%)
A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More?

Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist...

IOVA : 14.90 (+1.71%)
ORGS : 7.95 (-0.13%)
ARNA : 43.82 (-1.55%)
Initiating Free Research Reports on ArQule and Three Other Biotech Equities

Stock Research Monitor: AMAG, AMGN, and ARNA

ARNA : 43.82 (-1.55%)
AMAG : 21.85 (-1.35%)
AMGN : 190.49 (-0.66%)
Arena Pharmaceuticals (ARNA) Up 15.1% Since Earnings Report: Can It Continue?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ARNA : 43.82 (-1.55%)
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Seattle Genetics

NEW YORK, NY / ACCESSWIRE / June 1, 2018 / U.S. markets closed sharply lower on Thursday as the U.S. decided to impose tariffs on steel and aluminum imports from Canada, Mexico and the European Union....

ARNA : 43.82 (-1.55%)
Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot Barn, and Green Dot -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Haemonetics Corporation (NYSE:HAE),...

GDOT : 81.71 (+0.34%)
ARNA : 43.82 (-1.55%)
XPER : 16.45 (-1.20%)
HAE : 98.65 (-0.19%)
BOOT : 24.39 (-1.01%)
MGI : 6.30 (+0.64%)
Arena Pharmaceuticals to Present at Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer, will present at the following investor conferences:

ARNA : 43.82 (-1.55%)
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected

Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.

PTGX : 7.89 (-0.38%)
LGND : 231.88 (-0.28%)
ARNA : 43.82 (-1.55%)
EXEL : 21.29 (-0.23%)
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2018.

ARNA : 43.82 (-1.55%)
Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More

The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.

LGND : 231.88 (-0.28%)
JAZZ : 176.49 (-0.35%)
MRK : 62.52 (+0.02%)
AGN : 171.79 (-0.92%)
ARNA : 43.82 (-1.55%)
VRX : 23.40 (-3.43%)
PFE : 37.33 (-0.08%)
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018, after the close...

ARNA : 43.82 (-1.55%)
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8

SAN DIEGO , May 2, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate...

ARNA : 43.82 (-1.55%)
What's in the Cards for Arena (ARNA) This Earnings Season?

Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.

ADVM : 5.05 (-1.94%)
EBS : 54.26 (-0.75%)
ARNA : 43.82 (-1.55%)
VNDA : 20.80 (-0.72%)
Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, and Outpost Medicine, a biopharmaceutical company...

ARNA : 43.82 (-1.55%)
Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Arena Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Markets continued to rise on Tuesday as investor focus continues to shift from geopolitical concerns to strong corporate earnings from major U.S. companies....

GWPH : 146.22 (-1.61%)
ARNA : 43.82 (-1.55%)
Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ARNA : 43.82 (-1.55%)
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral,...

ARNA : 43.82 (-1.55%)
This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch

- Cardiology interventions and diagnostics are a big market, and the new field of remote monitoring, for arrhythmias and heart trouble, is a rapidly expanding component. Better remote monitoring technology...

ARNA : 43.82 (-1.55%)
TENX : 6.85 (-0.44%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.38 , FTNT +0.53 , CAKE -0.45 , PLT -0.28 , AEO -0.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed the week with most contracts 3 to 4 cents higher on Friday. Nearby September was up 4.1% since last Friday, with higher closes every day this week. Solid exports and drier weather fueled some bottom picking and short covering acti...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar